You are here

Index

The index relates to the hard copy.

A

accountability and management, 78–100

Accountable Authority, 3

acronyms and abbreviations list, 186–188

administered finances, 109–110

special account, 104, 105

administrative tribunal decisions, 87

advertising and market research, 171

age demographic of staff, 92

agency resource statements, 175–177

Akers, Christine, 72

alpha1-proteinase inhibitor deficiency, 59

anaemia, 71

annual performance reporting statement, 22–75

annual reports, 60

Anti-D (Rh D immunoglobulin), 28, 69

apheresis plasma, 38, 39, 165

donors, 8, 45

assets and asset management, 107, 111

administered items, 110

Audit and Risk Committee, 23, 24, 80, 81, 85, 163

Australian Bleeding Disorders Registry (ABDR), 9, 60, 64

Australian Blood Sector Systems and Data Roadmap 2018-22, 27

Australian Commission on Safety and Quality in Health Care (ACSQHC), 61, 70

Australian Haemophilia Centre Directors' Organisation, 48

Australian Haemovigilance Minimum Data Set, 60

Australian Information Commissioner, 46, 87

Australian Institute of Health and Welfare, 61

Australian National Audit Office (Auditor-General), 80, 87

Australian Public Service Commission Employee Census, 88–89

Australian Red Cross Blood Service (Blood Service), 10, 34, 44–46, 53

B

balance sheet, 107

Bio-Rad Laboratories Pty Ltd, 35, 50

Bioverativ Australia Pty Ltd, 35

bleeding disorders (haemophilia), 9, 60, 64

Blood 2018 Awards, 72

blood cells, see red blood cells

blood donors, 8, 45, 46

Blood Management Standard, 29, 69, 70

Blood Service, see Australian Red Cross Blood Service

BloodNet, 8, 11, 63, 64, 66

BloodNet User Reference Group, 63

BloodSafe eLearning Australia, 14, 58, 70, 71

BloodSTAR, 57, 60, 66

Board, 15–19, 85, 158–163

budget, see finance

Business Committee, 80, 85

Business Continuity Plan, 62

Business Plan, 85

C

C1 Esterase, 39, 168

Canadian Bleeding Disorders Registry, 64

Canberra, 46

capability reviews, 87

Chief Executive (General Manager), 3, 24, 51, 80, 81

classification of staff, 90–92, 97

clinical demand, 25, 37, 39–43

clotting factors, 40–42, 59

Comcare, reportable incidents lodged with, 100

Commonwealth Ombudsman, 87

communication and promotion, 69

competitive tendering and contracting, 112

conferences and events, 12, 51, 69, 72

consultants, 112–113

contingency events, 25

contingency plan, 25, 62

contracts, see purchasing

Corporate Plan, 23

Council of Australian Governments (COAG) Health Council, 3, 85

Criteria for the clinical use of intravenous immunoglobulin in Australia, 53, 55–58

critical care PMM module, 68

CSL Behring Pty Ltd, 34, 46–47, 49–50, 51, 166, 167, 168, 169

D

data developments, 60

data security breach, 46

Deed of Agreement, Red Cross, 10, 44–46

demand, 25, 37, 39–43

Deputy Chief Executives, 12, 24, 51, 80, 81, 82

diagnostic reagent products, 8, 35, 50

disability reporting, 174

discards, see wastage and discards

donors and donor management, 8, 45, 46

E

ecologically sustainable development, 171–173

education and training, 70–71

emicizumab, 59

employees, 11–12, 32, 80, 88–100

enterprise agreement, 95, 96

environmental performance, 171–173

establishment of NBA, 79

Executive Management Team, 81

exempt contracts, 112

expenditure, see finance

Extended Half-Life (EHL) clotting factor products, 12, 40, 41, 48

external scrutiny, 87

F

Factor VIIa, 41–42, 166

Factor VIII (rFVIII) products, 39, 40, 166–167

Factor IX (rFIX) products, 39, 41

finance, 3–4, 104–155, 175–177

financial assets, 107

financial statements, 114–155

fractionation, see plasma and recombinant products

fraud control, 87

freedom of information, 174

fresh blood, 33, 34, 36–39, 44–47, 165

full-time employees, 90–92, 94

G

gender of employees, 90–91, 94

General Manager, see Chief Executive

governance, 78–82

grant programs, 174

Grifols Australia Pty Ltd, 35, 47, 49, 50, 51, 168

H

haemophilia, see bleeding disorders

haemovigilance, 60, 61, 72

Haemovigilance Advisory Committee, 61

human resources, 11–12, 32, 80, 88–100

I

Immulab Pty Ltd, 35, 50

immunoglobulins (Ig), 27, 39, 43, 67, 168–169

imported supplies, 9, 35, 39, 43, 47, 49, 168–169

income, see finance

Indigenous employees, 96

information communication technology (ICT), 27, 64–66

Information Publication Scheme statement, 174

internal audit and risk program, 81

internal auditors, 80, 81

international environment, 12, 51

inventory management, 30

imported immunoglobulin, 49

imported plasma and recombinant products, 50

iron deficiency anaemia, 71

J

Johnson & Johnson Medical Pty Ltd, 35, 50

judicial decisions, 87

Jurisdictional Blood Committee (JBC), 12, 13, 27, 29, 59, 62

K

key performance indicators, see performance indicators/criteria

L

Learnhub, 93

legal decisions and actions, 87

legislation, 15, 61, 78, 79, 104, 105

liabilities, see assets

location of employees, 94, 96

M

McMaster University, 64

management and accountability, 78–100

market research and advertising, 171

maternity care, 68, 69

medical PMM module, 68

Medical Services Advisory Committee, 59

Ministers, 3

MyABDR portal, 64

N

National Blood Account, 104, 105

National Blood Agreement, 67, 73, 78, 79, 104

National Blood and Blood Product Wastage Reduction Strategy, 27

National Blood Authority Act 2003, 15, 61, 78, 79, 104, 105

National Blood Product Management Improvement Strategy, 60, 69

National Blood Sector Research and Development Program, 73–74

National Blood Sector Research and Development Strategic Priorities 2013-16, 73

National Blood Supply Contingency Plan, 25, 62

National Data and ICT strategy, 27

National Fractionation Agreement for Australia, 46–47

National Haemovigilance Report, 60

National ICT and Data Strategy, 27

National Ig Interest Group, 58

National Immunoglobulin Governance Advisory Committee (NIGAC), 58

National Inventory Management Framework (NIMF), 30

National Managed Fund (Blood and Blood Products) Special Account, 104, 105

National Patient Blood Management (PBM) Guidelines, 28, 29, 68, 70

National Patient Blood Management Implementation Strategy, 28, 69

National Policy: Access to Government Funded Immunoglobulin Products in Australia, 53–54, 55, 57

National Safety and Quality Health Service Standards, 29, 61, 70

National Supply List, 59

National Supply Plan and Budget (NSP&B), 33–43, 85

National Wastage Reduction Strategy, 27

neonatal and paediatric PMM module, 68, 70

New South Wales Ministry of Health, 53

non-English speaking backgrounds, employees from, 96

non-financial assets, 107

non-ongoing employees, 90, 91–92, 94, 96

non-salary benefits, 97–98

Novo Nordisk Pharmaceuticals Pty Ltd, 35, 49–50, 166, 168

O

objectives, 33–74

obstetrics and maternity, 68, 69

occupational health and safety, 32, 100

Office of the Australian Information Commissioner, 46, 87

Ombudsman, 87

ongoing employees, 90, 91–92, 94, 96

online services, see information communication technology

operating result, 106–110

organisation and structure, 2–19, 78–82

organisation charts, 4, 78, 79, 82

Ortho-Clinical Diagnostics, 35, 50

Output Based Funding Model (OBFM), 44, 45, 109

P

Parliamentary committees, 87

part-time employees, 90–92, 94

Pathology Queensland, 66

patient blood management, 28–30, 68–75

Patient Blood Management (PBM) Guidelines, 28, 29, 68, 70

people management, 11–12, 32, 80, 88–100

Performance Improvement Strategy for the Immunoglobulin Governance Program, 27, 54

performance indicators/criteria, 25–32

performance pay, 99

performance reporting statement, 22–75

perioperative PMM module, 68

Perros, Alexis, 72

Pfizer Australia Pty Ltd, 35, 49–50, 167

planning framework, 83–86

plasma and recombinant products, 33, 34–35, 39–43

plasma for fractionation, 34, 39, 46–47, 165

plasma only donor collection centres, 46

plasmapheresis, see apheresis plasma

platelets, 9, 38, 67, 72, 165

policy and policy advice, 31

Portfolio Budget Statements, 23

prices, 37, 39–40, 165–169

privacy incident, 46

procurement, see purchasing

productivity gains, 99

promotion and communication, 69

Prothrombinex, 39, 168

Public Governance, Performance and Accountability Act 2013, 23, 104, 105, 112

Public Governance, Performance and Accountability Rule 2014, 23, 87

Public Service Act 1999, 104

determination under Section 24(1), 96

publications distributed, 9

purchasing, 112–113, 170–171

purchasing of blood and blood product supply, 3–4, 33–51, 165–169

R

recombinant products, see plasma and recombinant products

red blood cells, 9, 37–38, 165

remuneration of staff, 96–99

research and development, 30, 72–74

resource statements, 175–177

returns to government, 37, 109

revenue, see finance

Rh D (Anti-D) immunoglobulin, 28, 69

risk management, 62, 81, 87

role, 2

S

safe and efficient use, see patient blood management

salary and remuneration, 96–99

Sanofi-aventis Australia Pty Ltd, 35, 48, 49–50, 167

satisfaction with Blood Service, 45

savings, 10, 37, 39, 43

sector monitoring, 67

security of supply, see supply

Service Charter, 85–86

Shire Australia Pty Ltd, 34, 48, 49–50, 166, 167–168

small business, procurement initiatives to support, 113, 170

special accounts, 104, 105

Specialist Working Groups, 55, 58

staff, 4, 11–12, 32, 80, 88–100

Staff Participation Forum, 80

standards, 29, 61, 70

STARS, 60

Statement on National Stewardship Expectations for the Supply of Blood and Blood Products, 69

Strategic Framework for the National Haemovigilance Program, 60, 61

supply, 8, 33–67, 165–169

supply chain management, see inventory management

T

tenders, see purchasing

Therapeutic Goods Administration, 61

Townsville, 46

training, see education and training

tribunal decisions, 87

V

values, 89

W

wastage and discards, 27

website services, see information communication technology

whole blood, 38, 39, 165

work health and safety, 32, 100

work plans, 24, 60

workforce, 4, 11–12, 32, 80, 88–100